Neoadjuvant therapy for pancreatic ductal adenocarcinoma—real effects or patient selection?

作     者：Stefan Heinrich 

作者机构：Department of General Visceral and Transplantation Surgery University Hospital of Mainz Mainz Germany 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2018年第7卷第4期

页      面：289-291页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：adenocarcinoma Surgery curative 

摘      要：Surgery is the only treatment with curative potential for patients with pancreatic ductal adenocarcinoma (PDAC).Unfortunately, the majority of patients do not qualify for curative resection due to locally advanced or metastatic disease at presentation.